ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Recent Advances in the Management of Metastatic Prostate Cancer
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 207910" data-attributes="member: 13851"><p><em>Management of metastatic prostate cancer has undergone a revolution over the past decade with the introduction of several novel agents and repurposing of others. Several clinical trials reported improved outcomes with the intensification of androgen deprivation therapy by the addition of docetaxel chemotherapy or novel hormonal agents (abiraterone, enzalutamide, or apalutamide) in the metastatic castration-sensitive state. Relugolix has been recently approved as the first oral gonadotropin-releasing hormone receptor antagonist agent with a superior cardiovascular side-effect profile, and serum testosterone suppression compared with a gonadotropin-releasing hormone agonist, leuprolide. Poly-ADP ribose polymerase inhibitors (olaparib and rucaparib) have demonstrated significant clinical benefit for patients harboring deleterious mutations in genes belonging to the homologous recombination repair pathway and have received Food and Drug Administration approval. Recently, lutetium-177- prostate-specific membrane antigen-617 with standard of care treatment has shown to improve overall survival in men with advanced-stage prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer. These recent approvals, successes, and the ongoing investigation of multiple novel agents are expected to continue to dramatically improve survival outcomes of men with metastatic prostate cancer in the coming years.</em></p><p></p><p></p><p></p><p></p><p><strong>INTRODUCTION</strong></p><p></p><p><em>In 2021, it is estimated that 26% of new noncutaneous cancer cases will be because of prostate cancer resulting in 11% of cancer-related deaths in the United States, making it the most common malignancy in men and the second leading cause of cancer mortality.1 Following the onset of metastatic disease, the disease is invariably fatal with a 5-year survival rate of only 30%. Furthermore, the incidence of metastatic prostate cancer seems to have increased in all races and age groups over the past decade.</em></p><p><em></em></p><p><em><strong>*Herein, we discuss the most recent advances in the management of metastatic prostate cancer and highlight recently approved agents and ongoing clinical trials. We will review the mechanism of action of recently approved agents (Table 1; Fig 1). We also present principles for optimal therapy selection based on clinical and molecular criteria, current roadblocks regarding treatment intensification in the castrate-sensitive stage, and challenges with treatment sequencing. Finally, we summarize promising therapies currently under development</strong></em></p><p></p><p></p><p></p><p></p><p><strong>*METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER</strong></p><p><em>Recent Approvals</em></p><p><em>Ongoing Investigations</em></p><p></p><p><strong>*METASTATIC CASTRATION-RESISTANT PROSTATE CANCER</strong></p><p><em>Recent Approvals</em></p><p><em>Ongoing Investigations </em></p><p></p><p><strong>*SELECTION OF PATIENTS</strong></p><p><em>Metastatic Castration-Sensitive Prostate Cancer</em></p><p><em>Metastatic Castration-Resistant Prostate Cancer </em></p><p></p><p><strong>*CHALLENGES AND FUTURE DIRECTIONS </strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong><em>In conclusion, an extraordinary pace of drug development and approvals have revolutionized the treatment paradigm of metastatic prostate cancer over the past decade. <u>The current era of targeted therapy, immunotherapy, theranostics, and the overall treatment of advanced prostate cancer will continue to evolve rapidly, and further improvements in survival outcomes are expected in the coming years</u>. These advancements in therapeutics will also pose new challenges in the clinic in terms of treatment selection and sequencing of therapies, and will increasingly require additional studies that focus on optimization of outcomes and minimization of cost and toxicities.</em></strong></p></blockquote><p></p>
[QUOTE="madman, post: 207910, member: 13851"] [I]Management of metastatic prostate cancer has undergone a revolution over the past decade with the introduction of several novel agents and repurposing of others. Several clinical trials reported improved outcomes with the intensification of androgen deprivation therapy by the addition of docetaxel chemotherapy or novel hormonal agents (abiraterone, enzalutamide, or apalutamide) in the metastatic castration-sensitive state. Relugolix has been recently approved as the first oral gonadotropin-releasing hormone receptor antagonist agent with a superior cardiovascular side-effect profile, and serum testosterone suppression compared with a gonadotropin-releasing hormone agonist, leuprolide. Poly-ADP ribose polymerase inhibitors (olaparib and rucaparib) have demonstrated significant clinical benefit for patients harboring deleterious mutations in genes belonging to the homologous recombination repair pathway and have received Food and Drug Administration approval. Recently, lutetium-177- prostate-specific membrane antigen-617 with standard of care treatment has shown to improve overall survival in men with advanced-stage prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer. These recent approvals, successes, and the ongoing investigation of multiple novel agents are expected to continue to dramatically improve survival outcomes of men with metastatic prostate cancer in the coming years.[/I] [B]INTRODUCTION[/B] [I]In 2021, it is estimated that 26% of new noncutaneous cancer cases will be because of prostate cancer resulting in 11% of cancer-related deaths in the United States, making it the most common malignancy in men and the second leading cause of cancer mortality.1 Following the onset of metastatic disease, the disease is invariably fatal with a 5-year survival rate of only 30%. Furthermore, the incidence of metastatic prostate cancer seems to have increased in all races and age groups over the past decade. [B]*Herein, we discuss the most recent advances in the management of metastatic prostate cancer and highlight recently approved agents and ongoing clinical trials. We will review the mechanism of action of recently approved agents (Table 1; Fig 1). We also present principles for optimal therapy selection based on clinical and molecular criteria, current roadblocks regarding treatment intensification in the castrate-sensitive stage, and challenges with treatment sequencing. Finally, we summarize promising therapies currently under development[/B][/I] [B]*METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER[/B] [I]Recent Approvals Ongoing Investigations[/I] [B]*METASTATIC CASTRATION-RESISTANT PROSTATE CANCER[/B] [I]Recent Approvals Ongoing Investigations [/I] [B]*SELECTION OF PATIENTS[/B] [I]Metastatic Castration-Sensitive Prostate Cancer Metastatic Castration-Resistant Prostate Cancer [/I] [B]*CHALLENGES AND FUTURE DIRECTIONS [I]In conclusion, an extraordinary pace of drug development and approvals have revolutionized the treatment paradigm of metastatic prostate cancer over the past decade. [U]The current era of targeted therapy, immunotherapy, theranostics, and the overall treatment of advanced prostate cancer will continue to evolve rapidly, and further improvements in survival outcomes are expected in the coming years[/U]. These advancements in therapeutics will also pose new challenges in the clinic in terms of treatment selection and sequencing of therapies, and will increasingly require additional studies that focus on optimization of outcomes and minimization of cost and toxicities.[/I][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Recent Advances in the Management of Metastatic Prostate Cancer
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top